Genzyme completes acquisition of Ilex Oncology, enters gene therapy collaboration with AGTC.
Genzyme notes Schering AG holds exclusive worldwide marketing and distribution rights, plus additional exclusive rights in the Pacific Rim for Campath. As part of the settlement with the Federal Trade Commission (FTC) prior to closing the acquisition the company transferred to Schering exclusive responsibility for the development and commercialization of Cantab in solid organ transplantation and Genzyme will no longer receive a share of US profits from the use of the product in transplantation.
The company says it remains committed to the transplantation market and will continue to support the development of Thymoglobulin and its pipeline of other products and candidates in the transplant field.
In addition, Genzyme announced it has entered into a research collaboration with Applied Genetic Technologies (AGTC), Gainesville, FL, a privately held company, to jointly develop novel therapeutics in gene therapy. The company says it has active preclinical development programs, including lysosomal storage disorders, cardiovascular disease, central nervous system and immune-related disorders which may benefit from AGTC's expertise in delivering genets to patients.
Contact: Web site: www.genzyme.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Applied Genetic Technologies|
|Article Type:||Brief Article|
|Date:||Jan 15, 2005|
|Previous Article:||Consensus conference on pancreas allocation, islet cell transplantation January 23-24 in Miami Beach.|
|Next Article:||DOR BioPharma reports orBec improves mortality rates in leukemia patients following bone marrow transplant.|